amgen
Sandoz Challenges Amgen in Antitrust Lawsuit to Launch Enbrel Biosimilar in the U.S.
Sandoz, Amgen, Enbrel, Erelzi, antitrust, biosimilar, etanercept, patent thicket, U.S. market, rheumatoid arthritis, competition, biologics, FDA approval.
Amgen Secures Phase 3 Survival Data for Imdelltra in Small-Cell Lung Cancer, Strengthening Its Case for Full FDA Approval
Imdelltra, Amgen, Small-cell lung cancer (SCLC), Phase 3 trial, Overall survival, DLL3-targeting therapy, Immunotherapy, Biopharmaceuticals
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
Amgen expands Indian footprint with $200M tech hub
Amgen, India, Technology, Site, Data Science, Aortic Valve Insufficiency, India ‘s
FDA Halts Amgen’s Phase 1 Obesity Drug Trial: AMG 513 Study on Hold
Amgen, obesity drug, AMG 513, FDA clinical hold, Phase 1 trial, pharmaceutical setback
Amgen and Celltrion Reach Settlement in Denosumab Patent Litigation, Paving Way for Mid-2025 Biosimilar Launch
Amgen, Celltrion, denosumab, patent litigation, biosimilar, settlement, launch date
Amgen Expands in North Carolina with $1 Billion Biomanufacturing Facility
Amgen, North Carolina, biomanufacturing, facility expansion, pharmaceutical industry
Amgen’s MariTide Shows Promising 20% Weight Loss, Falls Short of Investor Expectations
Amgen, MariTide, weight loss, obesity treatment, clinical trial results
Amgen Appoints Howard Chang as Senior Vice President of Research and Chief Scientific Officer
Howard Chang, Amgen, Chief Scientific Officer, Research, Biotechnology, Pharmaceutical Industry